Twist Bioscience, Revelar Say Data Show RBT-0813 Neutralizes Omicron, Delta Covid-19 Variants
© MT Newswires 2022
All news about TWIST BIOSCIENCE CORPORATION |
|
|
|
Analyst Recommendations on TWIST BIOSCIENCE CORPORATION |
|
|
| |
|
Sales 2022 |
196 M
-
-
|
Net income 2022 |
-253 M
-
-
|
Net cash 2022 |
229 M
-
-
|
P/E ratio 2022 |
-7,34x |
Yield 2022 |
- |
|
Capitalization |
1 953 M
1 953 M
-
|
EV / Sales 2022 |
8,78x |
EV / Sales 2023 |
7,03x |
Nbr of Employees |
652 |
Free-Float |
91,4% |
|
Chart TWIST BIOSCIENCE CORPORATION
Duration :
Period :
|

Technical analysis trends TWIST BIOSCIENCE CORPORATION
| Short Term | Mid-Term | Long Term | Trends | Neutral | Bearish | Bearish |
Income Statement Evolution
|
Mean consensus |
OUTPERFORM |
Number of Analysts |
8 |
Last Close Price |
34,72 $ |
Average target price |
40,50 $ |
Spread / Average Target |
16,6% |
|